Short answer “Bioidentical” simply means the hormone molecule is chemically identical to the hormone your body makes (for example, estradiol or micronized progesterone). Some bioidentical products are FDA‑approved prescription drugs; others are custom‑made (“compounded”) by pharmacies and are not FDA‑tested. Many doctors say FDA‑approved bioidentical hormone therapies can be safe and effective for appropriate patients when prescribed, dosed and monitored correctly. Most professional societies warn against unproven claims about compounded BHRT and recommend using FDA‑approved products whenever possible. What the evidence and major medical groups say For bothersome menopausal symptoms (hot flashes, night sweats, vaginal dryness) hormone therapy is the most effective treatment. Benefits and risks depend on the type of hormone, dose, route (oral vs transdermal vs vaginal), whether a progestogen is needed, your age, and your medical history. The Women’s Health Initiative (WHI) raised important safety concerns (increased risk of blood clots, stroke and, with combined therapy, a small increase in breast cancer). Later analyses clarified that risk varies: starting HT nearer to menopause and using lower doses tends to carry lower cardiovascular risk. Transdermal estradiol (patch/gel) and oral micronized progesterone appear to have lower venous thromboembolism risk than some oral estrogens or synthetic progestins. Vaginal low‑dose estrogen is effective for local urogenital symptoms with minimal systemic exposure. Major organizations (North American Menopause Society, Endocrine Society, American College of Obstetricians & Gynecologists) advise: use FDA‑approved products when possible, do individualized risk/benefit discussions, avoid marketing claims that compounded BHRT is safer or superior without evidence. Compounded BHRT: the concerns Compounded hormones are made by pharmacies to individual prescriptions and are not evaluated/approved by the FDA. Concerns include inconsistent dosing, purity, lack of clinical trials proving safety/effectiveness, and sometimes marketing that misleads patients (eg, “natural” = safer). That doesn’t mean compounding is never appropriate, but it should be used only when an FDA‑approved option truly won’t meet the patient’s needs and under careful supervision. Practical guidance — what to ask your doctor Do I actually need hormone therapy for my symptoms? What are the expected benefits? Which formulation (oral, patch, gel, vaginal) and which hormone do you recommend, and why? Can we use an FDA‑approved product? What are my individualized risks (clotting, heart disease, stroke, breast cancer)? How will we monitor? If you propose compounded BHRT, why is it necessary and what evidence supports it for my situation? Examples of FDA‑approved products (commonly used, bioidentical hormones) Estradiol patches/gels: Climara, Vivelle‑Dot, Alora (transdermal estradiol) — useful when avoiding first‑pass liver effects and may carry lower clot risk. Oral estradiol: Estrace (oral estradiol) — an FDA‑approved form of bioidentical estradiol. Micronized progesterone: Prometrium — FDA‑approved bioidentical progesterone used when a progestogen is required for women with a uterus. Vaginal/local products for urogenital symptoms: Vagifem (vaginal estradiol tablet), Estring (vaginal ring), Estrace cream — low systemic absorption for local symptoms. Trusted sources and services North American Menopause Society (NAMS) — evidence‑based guidelines and a clinician directory. Endocrine Society and American College of Obstetricians & Gynecologists (ACOG) — clinical practice guidelines. Reputable academic clinics (Mayo Clinic, Cleveland Clinic, major university women’s health/menopause clinics) for second opinions or complex cases. When BHRT might be appropriate Short‑term treatment for moderate–severe menopausal vasomotor symptoms in healthy women, especially those who are younger (<60) or within about 10 years of menopause, is a common and accepted indication when individualized. Vaginal estrogens are appropriate for bothersome local symptoms at any age in many cases. Testosterone for low libido in women is sometimes considered off‑label in specialized care, but it isn’t broadly FDA‑approved for women. When to be cautious Personal or strong family history of breast cancer, active liver disease, unexplained vaginal bleeding, or a history of venous thromboembolism typically prompt avoidance or extra caution and specialist consultation. Bottom line BHRT can be safe and effective when it’s an FDA‑approved product prescribed after a careful, individualized discussion of risks and benefits and with appropriate follow‑up. Be skeptical of broad “natural” safety claims for compounded BHRT; if your clinician recommends compounded products, ask why an FDA‑approved option won’t work and what monitoring will be done. If you’d like, tell me a bit about your age, symptoms and medical history and I can outline options you can discuss with your clinician.
Mentioned in position 9 of 10
Read full answer with sources →